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We summarize research approaches and findings on bone healing and regeneration that were presented at a
workshop at the 60th annual meeting of the Orthopedic Research Society (ORS) in New Orleans in 2014. The
workshop was designed to discuss the role of inflammation in bone regeneration in the context of fundamental
biology, and to develop therapeutic strategies that involve immune modulation. Delayed or non-healing of bone
is a major clinical problem, with around 10% of fracture patients suffering from unsatisfying healing outcomes.
Inflammation is traditionally seen as a defense mechanism, but was recently found essential in supporting and
modulating regenerative cascades. In bone healing, macrophages and T- and B-cells interact with progenitor cells,
bone forming osteoblasts and remodeling osteoclasts. Among the cells of the innate immunity, macrophages are
promising candidates for targets in immune-modulatory interventions that would overcome complications in bone
healing and bone-related diseases. Among the cells of the adaptive immune system, CD8+ T cells have been shown
to have a negative impact on bone fracture healing outcome, whereas regulatory T cells could be promising candidates
that have a positive, modulating effect on bone fracture healing. This workshop addressed recent advances and key
challenges in this exciting interdisciplinary research field.
Keywords: Osteoimmunology; Regeneration; Macrophages; Immune modulation; Bone healing; RevascularizationIntroduction
Bone healing
Vertebrates have a bony skeleton that acts as a scaffold
for the body. Healthy bone has a remarkable capacity for
self-repair (Figure 1). Although bone healing is for the
most part an efficient process, around 10% of patients
suffer from delayed healing or non-union, leading to the
application of complex, expensive, and often invasive,
treatment strategies [1].
Fracture healing is a highly complex process that includes
the participation of different cell types (immune cells,
progenitor cells, mesenchymal cells) [2] and their signal-
ling molecules (cytokines, growth factors, chemokines)
[3]. The healing process, which is initiated after injury,
results in effective reconstitution of the initial structure
of bone tissue, without scar formation. The regenerative* Correspondence: georg.duda@charite.de
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in any medium, provided the original work is preconstitution can be divided into several consecutive steps:
inflammation, soft callus formation, hard callus formation,
and remodelling (Figure 2).
The inflammatory phase starts with the formation of a
hematoma caused by the influx of blood following tissue
injury and vascular disruption. Because of its angiogenetic
and osteogenetic potential, the formation of fracture
hematoma in the early healing phase is an indispensable
step for successful healing [4,5]. Removal of the early frac-
ture hematoma was shown to impair bone healing in ani-
mal studies, whereas transplantation of the hematoma
leads to ectopic bone formation [6,7], demonstrating its
osteogenic potential. During the inflammatory phase, the
fracture area is characterized by hypoxia (low pH, high
lactate) that induces expression of the transcription factor
Hypoxia inducible factor 1α (Hif1α) that further triggers
the expression of angiogenic factors such as Vascular
Endothelial Growth Factor (VEGF). Revascularization is a
prerequisite for the repair phase, including the formation
of new cartilage and finally new bone (Figure 3). Immune
cells, located in the fracture area, release cytokines as as an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Figure 1 Bone healing. A regenerative process leading to bone formation with restored form/ function if successful. A: Intramembranous
bone formation along osteomized cortical bone (CB) clearly shows the newly formed woven bone (WB) on the left. Further from the bone edge
connective tissue is visible, that remains in the osteotomy gap at this healing stage. B: The difference between lamellar bone (CB) on the right is
clearly visible when compared to the heterogeneous newly formed woven bone (WB) on the left. Important cells in bone formation: C: Cells
depositing new bone are osteoblasts. The small black and white image explains this image. The arrow indicates an osteoblast in typical palisade
form sitting in a row with other osteoblasts on the surface of newly synthesized bone. The region marked with a line and stained blue in “C” shows
osteoid (OI), the extracellular matrix, yet unmineralized, synthesized by the osteoblasts. Freshly embedded in the newly formed woven bone at least 4
osteocytes can be seen, surrounded by mineralized matrix (★). D: Endochondral bone formation is initiated by a cartilaginous phase, with chondrocytes
becoming hypertrophic and then being replaced by osteoblasts and woven bone. E: Osteoclasts (OC) are multinuclear bone resorbing cells, sitting on
the bone surface. Clearly visible is the ruffled border, which is the actual bone resorbing area of the active osteoclast. (Images are taken from a large
animal bone healing model in sheep, 3 mm osteotomy gap, stable external fixation, staining: Alcian blue).
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of mesenchymal stromal cells (MSC) to the site of injury
where they further proliferate and differentiate thus pro-
moting revascularization.
Osteoimmunology
The immune and skeletal systems share a number of
regulatory and signaling molecules. This cross-linkage of
the immune and skeleton systems has led to new direc-
tions in research and the emergence of “osteoimmunology”
[9]. Bone is constantly remodelled due to the action of
osteoblast and osteoclast. Osteoblasts are bone-producing
cells which are derived from MSCs. Osteoclasts are the
bone resorbing counterparts to bone forming osteoblasts.
They differentiate from hematopoietic stem cells (HSC)and thus share the same progenitor as cells of the immune
system (Figure 4).
In numerous autoimmune diseases, disorders of the
skeletal system are commonly found. This has highlighted
the fact that there is little known concerning the direct
and indirect interactions between bone and the immune
system [10-12]. However, recent research clearly showed
the influence of the immune system on the bone healing
success [13], thus identifying the immune system as a
possible tool for new therapeutic approaches. The inter-
connectivity and complexity of cellular and molecular
interactions between the immune system and bone tis-
sue creates a major challenge to develop therapeutic
approaches that can specifically target one system with-
out detrimentally affecting the other. With aging of the
Figure 2 Different phase of the bone healing process. This scheme shows the consecutive/partly overlapping bone healing phases (I-IV)
occurring in secondary bone healing. The illustration follows the tissue coloring of the histological Movat‘s Pentachrome staining, where bone
appears yellow, cartilage appears green, bone marrow is purple, vessels are depicted in red.
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this interplay appears to be crucial.
Review
Impact of the immune system on bone fracture healing
Innate immunity
Macrophage Innate immunity is the first line of defense
to recognize and attack pathogens entering the body. This
includes physiological barriers (epithelial and mucosa) but
also cellular defense mechanisms accomplished by macro-
phages, mast cells and natural killer cells [14].
The innate immune system plays an important role in
tissue repair and in maintaining tissue homeostasis. Among
the cells of the innate immunity, tissue resident macro-
phages are recognized as key elements for the orchestration
of the recovery processes to re-establish tissue integrity
and function after damage [15]. Macrophages, originally
believed to be solely pro-inflammatory and destructive
phagocytes, were found in 1992 to have ability to convert
to a pro-healing phenotype [16]. Since then, it has been
shown that macrophages are necessary for angiogenesis,
wound healing, tumor growth, and limb regeneration
[17-20]. To distinguish this new phenotype from their
familiar “classically activated” counterparts, these mac-
rophages were referred to as “alternatively activated”. Since
then, these “M2” macrophages, named following the helper
T cell nomenclature (Th1/Th2) and in contrast to pro-
inflammatory “M1” macrophages, have been associated
with the resolution of wound healing in vivo in chronic leg
ulcers [21], atherosclerotic lesions [22], traumatic spinalcord injury [23], and inflammatory renal disease [24]. For
research studies and therapeutic applications, monocytes
isolated from peripheral human blood can be differenti-
ated into macrophages through the addition of the mono-
cyte colony stimulating factor MCSF, and polarized to
different macrophage phenotypes via the addition of spe-
cific cytokines [25] (Figure 5).
Depending on the micro-environment, macrophages
display distinct activation (also called polarization) states.
They are divided into the “classical activated” pro-
inflammatory M1 type macrophages and into the “alterna-
tively activated” anti-inflammatory, pro-tissue regeneration
and repair M2 type macrophages. Within the M2 popula-
tion, there are different subtypes, characterized by their
surface receptor expression and cytokine secretory profile,
as: M2a (anti-inflammatory), M2b (immune-regulatory)
and M2c (remodelling) [26] (Figure 6).
Role of macrophages in joint replacement-induced
osteolysis: an example of osteoimmunology
Total joint replacement (TJR) is a successful orthopaedic
intervention for end stage arthritis. Wear particles are an
unwanted by-product of all TJRs and are the cause for the
development of chronic inflammation at the implant site
[27]. A consistent inflammatory reaction leads to delayed
osseointegration of the implant and finally to osteolysis
(periprosthetic bone loss) and implant loosening. So far,
there are no nonsurgical treatment strategies to overcome
wear particle-induced osteolysis. Macrophages are one
of the first cells infiltrating the inflammatory reaction
Figure 4 Interactions between osteoclasts and immune cells in a mouse osteotomy model. In areas of newly formed woven bone
(14 days after fracture, mouse model) the tight interaction between osteoclasts (green (katepsin K)) and immune cells (T cells = red (CD3);




Figure 3 Onset of revascularization in bone healing. Seven days after performing a standardized osteotomy in a sheep‘s tibia, the maturating
granulation tissue clearly shows newly formed vessels (A: hematoxilin-eosin staining; 20 × magnification, B: α-SMA, methylgreen counterstaining,
vessels depicted in red, 40 × magnification). For these vessels to be this highly developed, revascularization in the hematoma must have started
earlier. C and D (Alcian blue staining): The importance of the revascularization becomes evident when observing the cutting edge of cortical
bone (CB) where a high number of vessels developed between bone and granulation tissue remnants (GT). The density of this capillary formation
is illustrated in D, where endothelial cells, indicating vessel borders, lie nearly wall to wall.
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Figure 5 Derivation of subsets of human macrophages from monocytes. Monocyte-derived macrophages were exposed to M1- or
M2-polarizing stimuli for 3 days followed by polarizing stimuli of the other phenotype for an additional 3 days (M1- > M2 and M2- > M1).
Unstimulated macrophages (M0) or macrophages cultured under M1- or M2-polarizing stimuli for 6 days (M1 and M2), with a media change at
day 3, served as controls. Reproduced with permission from [8].
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plasticity, macrophages could be a promising therapeutic
target, in the special case of wear particle-induced oste-
olysis to enhance osseointegration of the implant, and
in general to enhance bone healing.
One main key regulator for the migration and infiltra-
tion of monocytes and macrophages is the monocyte
chemoattractant protein-1 (MCP-1) [29]. Gibon et al.
showed in 2012 that a systemic therapeutic intervention
in the MCP-1-CCR2 chemokine-receptor axis (CCR2 is
the receptor for MCP-1) leads to less systemic migration
of macrophages to the site of particle infusion and fur-
ther, to decreased osteolysis [30,31]. The reverse effect
was observed after local administration of MCP-1. This
study gave the first hint that the MCP-1-CCR2 axis plays
an important role in the recruitment of macrophages to
the localization of wear particles. It also showed that
bone injury is not only a local event but rather a sys-
temic process affecting further tissues and organs. Block-
ing of the MCP1-CCR-2 axis by addition of a mutant
MCP-1 protein, 7ND, which competes with MCP-1 for
the binding to CCR-2 on macrophages, leads also to a
decreased migration of macrophages in vitro. In vivo
studies using 7ND are currently in progress. In thepresence of 7ND, a diminished secretion of pro- as well as
anti-inflammatory cytokines by macrophages was observed
([32,33]). The simultaneous decrease of pro- and anti-
inflammatory cytokine secretion could be explained by a
re-establishment of the homeostatic status. Both studies
illustrate the crucial role that macrophages play in
regulating inflammatory processes in bone probably
due to their secreted cytokine profile. An investigation of
the responsible macrophage subset would be an interesting
and indispensable question to answer with regard to the
development of nonsurgical treatment approaches for wear
particle-induced osteolysis in humans. Recent in vitro and
vivo studies have demonstrated that polarization of macro-
phages from an M1 to an M2 phenotype using local deliv-
ery of IL-4 mitigates wear particle-induced bone loss [34].
Modulation of macrophages in tissue engineering
approaches: revascularization of bone grafts
In tissue engineering, revascularization of the transplanted
tissue is a crucial prerequisite for a complete integration
and functionality of the transplant in the host. Living,
functional bone grafts, customized to the patient´s need,
are of great clinical need e.g. in the case of congenital
abnormalities, cancer resections and trauma [35].
Figure 6 During bone regeneration different types of macrophages are found in a mouse osteotomy model. M1 macrophages positive
for the CD68 macrophage marker and the M1 marker CD80 are found, for the M2 macrophages we detected cells positive for CD68 and CD163
and other M2 macrophages positive for CD68 and CD 206.
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the patient’s own stem cells capable of osteogenesis and
vasculogenesis, biomaterial scaffolds that act as a template
for bone formation, and a bioreactor providing nutrition,
oxygen supply and regulatory signals. In an ideal case,
the missing or defective bone should be repaired using
a living, functional bone graft that corresponds to the
exact shape of the bone being replaced or regenerated.
Current studies are achieving this goal through the use
of the patient’s own stem cells and image-based and
guided scaffold and bioreactor design. One of the main
challenges is to ensure the revascularization with blood
perfusion of the bone graft, to maintain its viability and
function. The developing vasculature guaranties the needed
supply of nutrients and, during normal development,
serves as a template for the forming bone. Therefore,
for successful bone tissue engineering strategies a syn-
ergistic formation of the new bone and new blood
vessels is an indispensable condition [36].
Because of their early appearance in inflammatory pro-
cesses, the action of macrophages and their polarization
state could be important for vascularization of implanted
bone in humans [24].It is still unclear what are the exact roles of various
macrophage subsets in vascularization of biomaterials.
To answer this question, Spiller et al. analysed the expres-
sion profiles of M1, M2a and M2c polarized macrophages
in vitro with focus on the expression of genes and proteins
important for angiogenesis. They also analysed the pro-
angiogenetic potential of conditioned media from these
polarized macrophage subsets in an in vitro sprouting
assay with human endothelial cells. Interestingly, it was
not one single subset of macrophages acting as the key
regulator of vasculogenesis. Instead, an interplay between
the M1 and M2 subset gave the best pro-angiogenic
stimuli.
In order to confirm the findings from the in vitro stud-
ies, the vascularization process and the macrophage
phenotype were evaluated in vivo. The following collagen
scaffold types were subcutaneously implanted in a mouse
model: glutaraldehyde-crosslinked (initiation of a moder-
ate inflammatory response expected), soaked in LPS (M1
polarization expected) and unmodified (control). Ten days
post-implantation, the scaffolds and the surrounding tis-
sue were analysed with regards to the appearance of blood
vessels (histological staining for CD31) and macrophage
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tween M1 and M2). The unmodified scaffold showed no
vascularization and was surrounded by a fibrous capsule
in which was detected a strong signal for M2 macro-
phages. As expected, in the LPS soaked scaffold there were
large numbers of inflammatory cells but no blood vessels,
and were strongly stained for the M1 subset. In the third
scaffold type, which was well vascularized, a staining for
both, M1 and M2 macrophages was observed [24].
Taken together the findings of this study suggest that
coordinated involvement of both subsets of macrophages
guides new blood vessel formation (Figure 7). A model was
proposed in which M1 macrophages promote sprouting of
blood vessels via secretion of VEGF, bFGF, IL8, RANTES,
and TNFalpha; M2c macrophages support angiogenesis, by
increasing vascular remodeling via production of MMP9;
M2a macrophages promote fusion of blood vessels through
currently unidentified secreted factors. M2a macrophages
may also regulate the actions of M1 macrophages via pro-
duction of TIMP3, and may recruit pericytes via secretion
of PDGF-BB. The interplay between M1 and M2 macro-
phages in regulating angiogenesis, and particularly the
effects of timing requires much more work [24].
Adaptive immunity
The adaptive (acquired) immune system is characterized
by high antigen specificity. Main cell types of the adaptive
immunity are B and T cells that recognize non self-
proteins by their highly specified antigen receptors. The
uniqueness of the adaptive immune system is the enor-
mously high variety of these antigen receptors whereby a
vast number of different antigens can be detected. Another
important characteristic of the adaptive immune system is
its memory. The memory enables a much faster reactionFigure 7 Proposed model for macrophage-mediated angiogenesis.
M1 macrophages promote sprouting of blood vessels via secretion of
VEGF, bFGF, IL8, RANTES, and TNFa. M2a macrophages promote fusion
of blood vessels through as-yet unidentified secreted factors. M2a
macrophages may also regulate the actions of M1 macrophages
via production of TIMP3, and may recruit pericytes via secretion of
PDGF-BB, although this was not directly assessed in this study. M2c
macrophages may function in vascular remodeling, given their high
levels of production of MMP9. Reproduced with permission from [28].of this part of the immune system during a renewed con-
tact with an already known antigen. Besides activation of
the cells of the adaptive immune system via their receptors,
another possible activation occurs via signals released by
the innate immune system demonstrating the high inter-
connectivity between both parts of the vertebrate immune
system.
In addition to its obvious crucial role in the fight
against pathogens, the adaptive immunity also plays an
important role during the healing process of a fractured
bone, illustrating the interdependency between the bone
and the immune system [37].
Negative impact of the immune system in the
regenerative processes After an injury, the disruption of
the blood vessels leads to hematoma formation that is ac-
companied by inflammation. This immediate body reac-
tion is a phylogenetically ancient, adaptive response [38].
In the context of wound healing, it is an indispensable
step for the initiation of the healing cascade [4]. Wound
healing is a multistage and complex process including a
multitude of different regulatory mechanisms and mole-
cules, especially in the inflammatory reaction, determining
the course of regeneration versus scar formation.
One of the key factors could be the age of the adaptive
immune system. Whitby and Ferguson [39] showed that
wounds in early mammalian embryos heal without scar
formation [39]. At these early stages, the immune system
is not yet fully developed. This leads to the assumption,
that a fully developed immune system thought to be per-
fectly adapted to act against the invasion of pathogens,
could have a negative impact in the course of wound
healing (Figure 8). This raises the question whether the
evolutionary development of such a highly efficient
immune response takes into account drawbacks for the
body’s regenerative capacity. The immune system ages
throughout the life of an individual. Therefore, the cel-
lular composition is different between a young and an
older organism that has been exposed to a multitude of
antigens and developed an immune memory. This aging
process could be the reason for the diminished regen-
erative capacity of bone in the aged. This assumption is
confirmed by the finding of an enhanced healing after
rejuvenation of the immune system [40]. Furthermore,
mice with a blunted immune system (germ free housing)
develop a significant higher bone density compared to
control animals [41].
The question is: Do certain cells of the adaptive immun-
ity have a negative impact on wound healing? The answer
is yes: CD8+ T cells as part of the adaptive immune re-
sponse were found to negatively influence wound healing
[42,43]. They could therefore be a promising therapeutic
target in wound healing treatment strategies in general
and especially in bone healing because the bone marrow
Figure 8 Bone healing in mice under different housing conditions. Analyzing bone healing in a mouse, which has been raised in a SPF
(specific pathogen free) surrounding (WT) and a mouse, that had contact with pathogens and thus the possibility to develop its adaptive
immune system (higher effector/ memory T cell count) (Wtexp): it became apparent, that the exposed animals showed a diminished healing
capacity when compared with animals of SPF raising. This was documented through μCT evaluation showing lower bone mineral density and a
lower bone volume/total volume in exposed animals. This data has been earlier published in the context of the negative influence of terminally
differentiated CD8+ T cells in bone healing [13].
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higher percentage of CD8+ T cells than CD4+ T cells
under physiological conditions [44]. Reinke et al. has
shown in humans that an enhanced level of terminally
differentiated effector memory CD8 +T cells correlates
with delayed fracture healing. This was further confirmed
in a mouse osteotomy model where a specific depletion of
CD8+ T cells led to an improved bone healing [13].
Whether the cells themselves or their secreted cytokines
have to be finally targeted has still to be evaluated.
Positive impact of the adaptive immune system in
regenerative processes The T cell population is highly
diverse. These cells secrete different inflammatory cytokines
and proteins (like Wnt ligands) and thereby promote bone
resorption and bone formation, respectively. Furthermore,
bone homeostasis is regulated by T cells via their crosstalk
with bone marrow stromal cells. Among the T cell popula-
tion, CD4+ and CD8+ T cell subsets seem to play different
roles in bone formation. In vitro studies showed that the
osteogenetic differentiation in human MSC cultures signifi-
cantly increases with conditioned media of unstimulated
CD4+ T cells. This was further confirmed by the up-Figure 9 Beneficial and unfavourable immune cells in bone healing. T
vessel disruption during injury, is an important criterion towards successful
influence on regenerative processes have been determined which are depregulation of the expression of osteogenic markers such as
runt-related transcription factor 2 (Runx2), osteocalcin
(OC), bone sialoprotein (BSP), and alkaline phosphatase
(ALP) [45]. In contrast, no such effect was seen with
the conditioned medium from CD8+ cells. A positive role
of CD4+ T cells was further evaluated in wound healing
without identifying the responsible subset [42]. Regulatory
T cells, a subpopulation of CD4+ T cells, are a promising
candidate for a positive regulator in wound and bone heal-
ing. Several studies cement this assumption.
A correlation between high bone mass and decreased
bone resorption was observed in mice with an increased
amount of regulatory T cells [44,46]. In addition, regula-
tory T cells counteract transplant rejection due to their
tolerogenic capacity [47], have a negative impact on
osteoclasts [48] and were shown to enhance bone healing
of a skull defect in mice when integrated in autologous
bone graft [49] (Figure 9).
Conclusion
The current therapies for the treatment of non-healing
bone fractures and bone disease are still unsatisfactory.
Fracture healing is a highly complex process involvinghe cellular composition of the bone hematoma that forms upon
healing. To date certain cells of the adaptive immune system and their
icted in this figure.
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inflammatory and immune system. For a successful heal-
ing outcome, the spatial and temporal interplay of these
different components has to be well orchestrated. There-
fore, in-depth understanding of bone regeneration on the
molecular, cellular and tissue level is indispensable for the
development of new therapeutic approaches.
Both the innate and adaptive immunity play a crucial
role by initiating and regulating the healing cascades.
The impact of immune cells in musculoskeletal diseases
illustrates how crucial it is to better understand the
signaling processes during the inflammatory phase of
healing. This importance is further supported by the
growing needs of our aging population, where the risk
of fracture and poor recovery become more frequent.
The aging population presents new challenges to both
clinicians and researchers.
To develop new treatment strategies, the challenges
we need to address include: (i) An early assessment of
poor healing so that advanced treatment options can be
implemented as soon as possible, for best outcomes, and
(ii) Timely coordination of the therapeutic intervention
with the progression of healing. There are already several
approaches developed to address each of these aspects.
Based on a better understanding of the signaling cascades
and the types, roles and timing of presentation of the par-
ticipating molecules and cells, a biomarker to “predict”
the healing outcome of a patient would be most useful. In
this context, the finding that a special subset of CD8+ T
cells has a negative impact on fracture healing is already
an important step in the early clinical evaluation of frac-
tured patients.
The use of biomaterials to support the healing process
is another important aspect in treating musculoskeletal
disease. Biomaterials are used as a structural template
for the regenerating tissues, including bone, and at the
same time they can function as a source of biological
factors. A biomaterial can be designed to optimize the
regenerative mechanisms by delivering the right amounts
of factors at the right time and to the right location within
the bone healing area. The new generation of biomaterial
scaffolds is being designed to recapitulate the local cyto-
kine and/or growth factor milieu of development and
remodeling, and to stimulate specific cell subsets to prolif-
erate and differentiate in the desired and patient-specific
way. One example discussed at the workshop was the
incorporation of factors recruiting M1 macrophages over
an initial period of time (to initiate vascularization) along
with the factors (immobilized for sustained action) to
recruit M2 macrophages (to mature and stabilize vascula-
ture). So far, little is known about the specific role of the
M1 and M2 types in the different musculoskeletal diseases
and healing phases (e.g. revascularization of a fractured
bone or a bone transplant) and further research is neededto evaluate their potential. This ORS workshop from
2014 with its topics of osteoimmunology in fracture
healing, joint replacement loosening, and in vitro model
systems demonstrates the wide spectrum of bone-immuno-
interplay. Future research should pay attention to this
relevant field.
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